The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2

NCT07146230 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Durvalumab
DRUG: Monalizumab
DRUG: Oleclumab
RADIATION: Radiotherapy

Sponsor

Montefiore Medical Center

Collaborators

[object Object]